Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 08, 2020 at 10:17 pm IST
Share
Li Kang Biomedical Co., Ltd. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 156.844 million compared to TWD 98.391 million a year ago. Operating income was TWD 32.758 million compared to TWD 13.677 million a year ago. Net income was TWD 25.365 million compared to TWD 11.153 million a year ago. Basic earnings per share was TWD 1.14 compared to TWD 0.5 a year ago. For the nine months, sales was TWD 291.065 million compared to TWD 345.096 million a year ago. Operating income was TWD 41.804 million compared to TWD 59.431 million a year ago. Net income was TWD 37.851 million compared to TWD 49.416 million a year ago. Basic earnings per share was TWD 1.71 compared to TWD 2.23 a year ago. Diluted earnings per share was TWD 1.7 compared to TWD 2.21 a year ago.
Li Kang Biomedical Co., Ltd. formerly BAFO TECHNOLOGIES CORP., is engaged in the manufacture and sale of computer, communication and consumer (3C) product cables and circumscribed computer peripheral products, as well as communication products. The Company offers unshielded twisted pair (UTP) cables, monitor cables, small computer system interface (SCSI) cables, universal serial bus (USB) cables, wireless hopping/mesh access points, wireless modules, and wireless vehicle communication systems, among others. The Company distributes its products within the domestic market and to overseas markets, including Europe, the Americas and the rest of Asia.
LI KANG BIOMEDICAL CO., LTD. 
